Drug Prices
The Senate Health, Education, Labor & Pensions Committee today held a hearing to examine how primary care affects health care costs and outcomes.
The Department of Health and Human Services’ Office of Inspector General yesterday proposed excluding from safe harbor protection under the Anti-Kickback Statute rebates paid by prescription drug makers to pharmacy benefit managers, Medicare Part D plans and Medicaid managed care organizations.
The Senate Finance Committee today held the first in a planned series of bipartisan hearings on high prescription drug prices and potential policy and oversight solutions to lower costs for patients.
Also in this weekly roundup of health care related news: Cleveland Clinic leader discusses health care trends, and how one health system uses real-time data to make clinical decisions.
Last week, I shared a few areas where we can advance health in America this year, even in a divided Congress. Number one on that list: reining in the skyrocketing costs of prescription drugs.
Continued rising drug prices, as well as shortages for many critical medications, are disrupting patient care and forcing hospitals to delay infrastructure and staffing investments and identify alternative therapies.
Drug spending is rising dramatically on top of historic growth. High drug prices create real challenges for hospitals and the patients they treat.
The ºÚÁÏÕýÄÜÁ¿ Association (AHA), the Federation of ºÚÁÏÕýÄÜÁ¿s (FAH), and the American Society of Health-System Pharmacists (ASHP) released a new report finding that continued rising drug prices, as well as shortages for many critical medications, are impacting patient care and…
We’re 11 days into 2019 … we’ve returned to a divided government …and the partial government shutdown continues.